» Articles » PMID: 8353277

Home Treatment with Intravenous Enzyme Replacement Therapy for Gaucher Disease: an International Collaborative Study of 33 Patients

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1993 Aug 15
PMID 8353277
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Intravenous enzyme replacement therapy (Alglucerase; Ceredase; Genzyme Corp, Boston, MA) is an effective and safe treatment for patients with type 1 Gaucher disease. In an attempt to reduce its high cost, a "low-dose high-frequency" protocol (30 U/kg/mo, 3 times a week) was introduced and found to be as effective as the original high-dose protocol (60 U/kg every 2 weeks). Because receiving frequent infusions creates a burden for many patients, we have implemented a program of home treatment for our patients. We now report the safety and feasibility of low-dose/high-frequency home intravenous enzyme-replacement therapy in 33 patients with Gaucher disease. The chronic nature of the treatment, its safety, lack of adverse effects, the stable condition of most patients, and the need to reduce the high cost make enzyme replacement for Gaucher disease a good candidate for intravenous home therapy.

Citing Articles

Home Enzyme Replacement Therapy in Gaucher Disease: A Review.

Kiec-Wilk B, Guijt P, Dan M, Abdelwahab M, Revel-Vilk S, Serratrice C J Clin Med. 2025; 14(3).

PMID: 39941513 PMC: 11818897. DOI: 10.3390/jcm14030842.


Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort Study.

Revel-Vilk S, Mansfield R, Feder-Krengel N, Machtiger-Azoulay N, Kuter D, Szer J J Clin Med. 2023; 12(18).

PMID: 37762854 PMC: 10531841. DOI: 10.3390/jcm12185913.


Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions.

Ditters I, van Kooten H, van der Beek N, Hardon J, Ismailova G, Brusse E BioDrugs. 2023; 37(5):685-698.

PMID: 37326923 PMC: 10432339. DOI: 10.1007/s40259-023-00609-2.


Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond.

Nowicki M, Bazan-Socha S, Klopotowski M, Blazejewska-Hyzorek B, Kusztal M, Pawlaczyk K Int J Environ Res Public Health. 2021; 18(16).

PMID: 34443990 PMC: 8394954. DOI: 10.3390/ijerph18168242.


A case with Gaucher disease unable to reach enzyme replacement therapy because of COVID-19 quarantine: The first case from Turkey.

Koc Yekeduz M, Kose E, Eminoglu F Turk Arch Pediatr. 2021; 56(3):270-271.

PMID: 34104921 PMC: 8152655. DOI: 10.5152/TurkArchPediatr.2021.21023.